There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), HCA Healthcare (HCA – Research Report) and Spectrum Pharmaceuticals (SPPI – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
SVB Securities analyst David Risinger maintained a Buy rating on Eli Lilly & Co on January 30 and set a price target of $410.00. The company’s shares closed last Tuesday at $344.15.
According to TipRanks.com, Risinger is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $400.20, which is a 17.5% upside from current levels. In a report issued on January 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $432.00 price target.
See the top stocks recommended by analysts >>
HCA Healthcare (HCA)
In a report issued on January 30, Whit Mayo from SVB Securities reiterated a Buy rating on HCA Healthcare, with a price target of $286.00. The company’s shares closed last Tuesday at $255.07.
According to TipRanks.com, Mayo is a 4-star analyst with an average return of
Currently, the analyst consensus on HCA Healthcare is a Strong Buy with an average price target of $279.07, a 10.0% upside from current levels. In a report issued on January 19, Oppenheimer also maintained a Buy rating on the stock with a $270.00 price target.
Spectrum Pharmaceuticals (SPPI)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Spectrum Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Tuesday at $0.70.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of
Spectrum Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $3.00, representing a 383.9% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- Eli Lilly says FDA approves Jaypirca
- Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park
- Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eli Lilly (NYSE:LLY) Faces Setback in Alzheimer’s Drug Approval
